Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.
about
Immunotherapy in Multiple Myeloma Using Cancer-Testis AntigensMyeloid-derived suppressor cells as therapeutic target in hematological malignanciesElotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Variation and significance of secretory immunoglobulin A, interleukin 6 and dendritic cells in oral cancer.Immune checkpoint blockade for hematologic malignancies: a reviewA multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patientsMultiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.Immunotherapy for multiple myeloma.T cell-based targeted immunotherapies for patients with multiple myeloma.Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progressionMonokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma.Docosahexaenoic acid (DHA) promotes immunogenic apoptosis in human multiple myeloma cells, induces autophagy and inhibits STAT3 in both tumor and dendritic cells.Monitoring NK cell activity in patients with hematological malignancies.Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma.Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
P2860
Q26774913-30A555D1-866A-4355-8264-8FBBE6A45120Q27010234-AEC60061-4B0D-4890-963F-D738C4D6634AQ30249513-37483B20-8BA0-4EB8-AEFC-6B5B62C2E20AQ33598073-85CF95AA-D4AF-4014-9280-9D8DFC1EE62AQ33645590-EF08A342-D9CF-4121-9EEB-667BAB582223Q34543937-538F50BA-2FBE-40C2-AF57-07E83A6441E0Q35833055-7E0EEFBE-3061-45CC-9853-C62345187880Q38155039-CBB9F348-0243-4F77-92AE-2BEE57AFF7C0Q38177879-36199A05-19C8-41F2-8CD4-4BA3A0FEE392Q38246639-099D76AD-4646-4C28-BB39-89898A5C80D1Q38526452-0115520F-EA76-4741-8822-969BCA2F8717Q38580545-4D0835AB-CACD-4E30-96A7-8BD7FC064A6CQ39136762-C0627FF3-0381-46FC-B7DC-8DFB70E7D896Q39901834-4B0CB6DD-3B8B-4E94-A525-58A30D40E75FQ41785517-549FF1E9-18AD-42E5-AB83-351935634764Q42847576-7DD9C1E5-96D8-40AA-9214-5BF283C50C9CQ47580433-1D0B778C-78D6-4757-BA2F-38CDDE329D4CQ57138927-29271D27-A2B3-4729-A432-B13D582AE6F6
P2860
Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.
@en
type
label
Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.
@en
prefLabel
Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.
@en
P2860
P356
P1476
Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes.
@en
P2860
P304
P356
10.1155/2012/196063
P5008
P577
2012-04-11T00:00:00Z